15 December 2023
Pharma's Almanac: Significant Regulatory Guidance on the Horizon for 2024
Pharma's Almanac
Pharma's Almanac asked industry experts, including ScaleReady's Global Director Josh Ludwig, their thoughts on the most significant regulatory decisions or guidance on the horizon for 2024. Josh discusses establishing more comprehensive and flexible guidelines for CGTs that will provide the clarity needed to enable creative, high-throughput manufacturing strategies.
14 December 2023
Pharma's Almanac: Consequential Events in Biopharma in 2023
Pharma's Almanac
Josh Ludwig, Global Director of ScaleReady, joins Pharma's Almanac and biopharma industry experts to discuss the most consequential events and results of 2023. Josh reviews how investment setbacks have instigated a pivotal paradigm shift in cell therapy manufacturing this year.
14 December 2023
European Pharmaceutical Manufacturer: Simplifying Cell and Gene Therapy
European Pharmaceutical Manufacturer
Before investing in advanced tech, manufacturers must fully understand AI and automation in the unique context of CGT production. Josh Ludwig, Global Director, ScaleReady writes about the importance of simplifying existing CGT manufacturing processes before integrating AI and automation, ensuring a smooth transition.
28 November 2023
Genetic Engineering & Biotechnology News: Scaling Up the Cell Therapy Industry
Genetic Engineering & Biotechnology News
To meet rising patient demand, the cell and gene therapy industry must rapidly scale up production through advancements in automation, talent acquisition, and supply chain management. Genetic Engineering & Biotechnology News discusses advancements in cell therapy industry growth, including the ScaleReady joint venture.
24 October 2023
Clinical Trials Arena: Promising Future for AI in Cell Therapy
Clinical Trials Arena
Technology is transforming healthcare, with a major focus on the development of precision medicine. Josh Ludwig, Global Director of ScaleReady, discusses the implications of automation and AI in cell therapy.
23 October 2023
The Medicine Maker: Industry 4.0 and Advanced Manufacturing
The Medicine Maker
The Medicine Maker gathered four experts, including ScaleReady's Josh Ludwig, to discuss what’s changed, what’s changing, and what the future looks like for Industry 4.0 in pharma manufacturing, knowing the industry traditionally lags somewhat in this uptake.
5 October 2023
pharmaphorum: Standardizing Workflows to Improve Efficiency
pharmaphorum
While innovation drove the early stages of cell therapy development, the industry is now transitioning to address the challenges of delivering these therapies to patients on a large scale. Josh Ludwig of ScaleReady emphasizes the importance of standardized workflows that are scalable and easily automated to improve efficiency.
27 September 2023
BioPharma Reporter: Jenny Stjernberg Discusses Her Passion for Cell and Gene Therapy
BioPharma Reporter
At Advanced Therapies Europe 2023, ScaleReady's Jenny Stjernberg spoke with BioPharma Reporter about her career path, company initiatives, and the importance of female representation in cell and gene therapy.
21 September 2023
BioProcess International: Prioritize Simplifying Processes Over Automating
BioProcess International
Automation is necessary for the future of CGT manufacturing to reduce contamination risk. However, as Jenny Stjernberg of ScaleReady highlights in this BioProcess International article, premature automation without simplifying processes can lead to longer timelines, increased risk, and financial strain.
15 September 2023
Pharma's Almanac: What Conventional Industry Wisdom is Misguided, Outdated, or Wrong?
Pharma's Almanac
Industry experts, including Jenny Stjernberg, Ph.D., Commercial Director, EMEA, discuss which conventional industry wisdom they believe is misguided, outdated, or just plain wrong with Pharma's Almanac. Jenny discusses how many developers have too-literally retained the conventional wisdom that for cell-based therapies "process is product."
15 September 2023
Pharma's Almanac: Leveraging Real-word Data in Cell and Gene Therapy
Pharma's Almanac
Cell therapies show remarkable potential in treating challenging lymphomas, as demonstrated by real-world data. But companies may run out of funds before reaching milestones due to factors like inefficient manufacturing, facility costs, and difficulties scaling processes. Alaina Schlinker, Ph.D., Senior Manager, Field Applications Support, ScaleReady, discusses how ScaleReady's platforms aim to help developers reach clinical milestones quickly and cost-effectively.
26 August 2023
RegMedNet Interview: Preserving flexibility and the significance of cryopreservation in every step of the cell and gene therapy workflow
In an exclusive interview with RegMedNet, Jenny Stjernberg discusses the crucial role of scalability in advancing groundbreaking therapies. Stjernberg emphasizes the importance of preserving flexibility while scaling up cell therapy manufacturing approaches.